United States Patent 7,361,649: What the β-Crystalline Ivabradine Hydrochloride Claims Cover
US 7,361,649 claims a specific polymorph of ivabradine hydrochloride, defined by powder X-ray diffraction (PXRD) peak metrics, and ties that polymorph to a crystallization process, a solid dosage composition, and therapeutic use.
Claim-set overview (what is protected)
| Claim |
Category |
Core protection logic |
Practical coverage |
| 1 |
Product |
“β-crystalline form” identified by essentially following PXRD data (2θ peaks with counts, FWHM, and d-spacing) |
Anyone selling, importing, or using this β-form material as such (if it matches the PXRD profile as claimed) |
| 2 |
Process |
Heat to dissolution then progressively cool until crystallization completes, using specified solvent systems |
Anyone making the β-form using that dissolution/cooling regime in those solvent conditions |
| 3 |
Process refinement |
Seeding during cooling |
Process variants that include seeding fall within narrower dependent claim |
| 4 |
Composition |
Solid composition with the claimed β-form plus pharmaceutically acceptable inert carriers |
Tablets/granules/capsules using this polymorph (as active) in solid dosage forms |
| 5 |
Method of use |
Treating angina pectoris, myocardial infarct, or heart failure by administering therapeutically effective amounts |
Downstream medical indication use (broader than formulation specifics) |
The claims are structurally typical of polymorph patenting: a product claim defined by PXRD, a process claim to make it, then composition and use claims that extend commercial and regulatory positioning.
What Claim 1 Actually Requires: PXRD-defined β-Crystalline Ivabradine Hydrochloride
Independent claim hook
Claim 1 is a product-by-structure claim anchored to PXRD. It requires that the β-crystalline form of ivabradine hydrochloride exhibits “essentially the following powder X-ray diffraction data” measured on a PANalytical X’Pert Pro diffractometer with an X’Celerator detector, and reported as Bragg angle 2θ (degrees), ray height (counts), ray area (counts × degrees), ray width at half-height FWHM (degrees), and interplanar distance d (Å).
PXRD peak list in the claim
The claim contains 34 numbered diffraction features. Key aspects for claim scope are (1) the set of 2θ positions and (2) the associated intensity/shape descriptors (counts, ray area, FWHM) plus calculated d-spacing.
| # |
2θ (deg) |
Ray height (counts) |
Ray area (counts × deg) |
FWHM (deg) |
d (Å) |
| 1 |
6.8 |
130 |
86 |
0.6691 |
13.019 |
| 2 |
9.2 |
6141 |
507 |
0.0836 |
9.613 |
| 3 |
9.7 |
882 |
58 |
0.0669 |
9.083 |
| 4 |
10.0 |
875 |
72 |
0.0836 |
8.837 |
| 5 |
11.9 |
190 |
19 |
0.1004 |
7.433 |
| 6 |
12.2 |
500 |
58 |
0.1171 |
7.236 |
| 7 |
13.2 |
224 |
30 |
0.1338 |
6.694 |
| 8 |
13.8 |
633 |
52 |
0.0836 |
6.419 |
| 9 |
14.3 |
466 |
54 |
0.1171 |
6.209 |
| 10 |
14.8 |
926 |
76 |
0.0836 |
5.977 |
| 11 |
15.0 |
716 |
94 |
0.1338 |
5.887 |
| 12 |
15.7 |
531 |
79 |
0.1506 |
5.636 |
| 13 |
16.1 |
121 |
16 |
0.1338 |
5.502 |
| 14 |
16.9 |
1354 |
223 |
0.1673 |
5.254 |
| 15 |
18.4 |
5672 |
562 |
0.1004 |
4.824 |
| 16 |
18.8 |
1328 |
131 |
0.1004 |
4.716 |
| 17 |
19.7 |
1617 |
347 |
0.2175 |
4.508 |
| 18 |
20.4 |
296 |
34 |
0.1171 |
4.341 |
| 19 |
20.7 |
767 |
51 |
0.0669 |
4.286 |
| 20 |
21.3 |
1419 |
211 |
0.1506 |
4.178 |
| 21 |
21.6 |
2458 |
243 |
0.1004 |
4.114 |
| 22 |
22.6 |
1737 |
258 |
0.1506 |
3.937 |
| 23 |
23.0 |
1467 |
73 |
0.0502 |
3.865 |
| 24 |
23.7 |
486 |
128 |
0.2676 |
3.751 |
| 25 |
23.9 |
504 |
50 |
0.1004 |
3.718 |
| 26 |
25.3 |
4606 |
304 |
0.0669 |
3.513 |
| 27 |
25.7 |
791 |
91 |
0.1171 |
3.464 |
| 28 |
26.2 |
458 |
91 |
0.2007 |
3.406 |
| 29 |
26.6 |
221 |
44 |
0.2007 |
3.352 |
| 30 |
27.4 |
706 |
151 |
0.2175 |
3.251 |
| 31 |
27.7 |
208 |
27 |
0.1338 |
3.215 |
| 32 |
28.1 |
483 |
40 |
0.0836 |
3.176 |
| 33 |
28.8 |
242 |
24 |
0.1004 |
3.096 |
| 34 |
29.3 |
450 |
74 |
0.1673 |
3.049 |
Scope implications of the PXRD definition
- Product “essentially” standard: The claim uses “essentially the following” list rather than “exactly.” That gives the patentee room against trivial measurement drift while keeping a definable diffraction signature anchored to the listed peaks.
- Multidimensional matching: The inclusion of ray height, ray area, and FWHM increases evidentiary specificity compared with peak-position-only polymorph claims. In infringement disputes, the defended material must align not only in 2θ positions but also in peak shapes/intensities as claimed.
- Instrument recitation matters: Claim 1 specifies PANalytical X’Pert Pro + X’Celerator detector and the reporting framework. This becomes relevant in validity and infringement testing because PXRD peak assignment and reported intensities depend on method settings.
What Claim 2 Covers: Crystallization by Dissolution Then Progressive Cooling
Solvent system and thermal profile
Claim 2 is a process for preparing the β-form of claim 1 by:
1) Heating a mixture of ivabradine hydrochloride and water, or a mixture of ivabradine hydrochloride, isopropanol, and water, until dissolution is complete; then
2) progressively cooling until crystallization is complete; then
3) collecting the resulting crystals.
Scope characteristics
- Broad solvent latitude within enumerated systems: The claim covers two routes: (a) water-only, (b) ivabradine HCl + isopropanol + water. It does not extend to ethanol, acetone, or other alcohol/water systems unless they fit the literal “isopropanol and water” wording.
- Process step structure: The legal structure is defined by “dissolution complete” then “progressively cooled until crystallization complete.” That limits the claim to crystallization regimes that follow the dissolution-then-cooling paradigm rather than, for example, antisolvent addition at ambient temperature or vapor diffusion.
What Claim 3 Adds: Seeding During Cooling
Dependent refinement
Claim 3 narrows Claim 2 by requiring that the solution is seeded during the cooling step.
Scope impact
- Inclusion of seeded variants: Any process that uses the same base solvent and dissolution/controlled cooling logic while adding a seeding step is captured by claim 3.
- Exclusion of non-seeded cooling-only versions from claim 3: A defendant can avoid claim 3 while still potentially falling under claim 2, depending on whether seeding is performed.
What Claim 4 Covers: Solid Pharmaceutical Composition
Composition definition
Claim 4 covers:
- a solid pharmaceutical composition
- having as active ingredient the β-crystalline form of claim 1
- combined with one or more pharmaceutically acceptable, inert, non-toxic carriers.
Scope characteristics
- Form is “solid,” not liquid: The claim targets solid dosage forms (e.g., tablets, capsules, granules). It does not read on liquid formulations.
- Carrier language is functional: “One or more pharmaceutically acceptable, inert, non-toxic carriers” is broad; it covers standard excipient classes used in solid oral formulations.
What Claim 5 Covers: Therapeutic Method
Indication set
Claim 5 covers a method for treating conditions selected from:
- angina pectoris
- myocardial infarct
- heart failure
by administering to a living animal body including a human a therapeutically effective amount of the β-crystalline form of claim 1.
Scope characteristics
- Active ingredient identity drives coverage: As in composition claims, the β-polymorph identity is central. The method claim does not require a particular dosage form or specific excipient composition.
- Indication-limited: It is limited to the listed cardiovascular conditions.
Patent Landscape (US 7,361,649): How It Typically Sits in a Polymorph Portfolio
The claim architecture places US 7,361,649 in the common ivabradine strategy: a known API is protected by polymorph-specific IP, with downstream use and formulation claims to support market exclusivity against competitors producing alternative solids.
Landscape map by claim layer
| Layer |
What US 7,361,649 protects |
Competitive workaround pressure |
| Product polymorph |
β-form defined by PXRD |
Competitors must identify a non-infringing polymorph or co-form that fails the “essentially” PXRD signature |
| Manufacturing process |
dissolution then progressive cooling, with optional seeding |
Competitors may shift to alternative solvent systems or alternative crystallization methods not matching claim 2/3 |
| Formulation |
solid compositions with this β-form |
Competitors can potentially use the same β-form but different solid carrier systems (still may infringe claim 4) or choose non-β polymorphs |
| Use |
treating angina, MI, heart failure |
If a competitor uses a different API or different polymorph not matching claim 1, they may avoid the β-specific method claim |
Where validity challenges usually concentrate for polymorph PXRD claims
- Whether the β-form is clearly and reliably distinguishable from other forms by the listed diffraction features.
- Whether “essentially” introduces indefiniteness when measurement conditions shift.
- Reproducibility: Whether other labs under comparable PXRD settings can reliably classify materials as the β-form per the listed peak metrics.
Actionable Claim-Focus Checklist for Freedom-to-Operate (FTO)
If evaluating infringement risk for a competitor material
1) PXRD classification: Confirm whether the competitor material’s PXRD profile matches the 34 listed peaks sufficiently across 2θ positions and peak shape metrics (height/area/FWHM) as captured in claim 1.
2) Measurement method comparability: Determine whether their lab used a comparable instrument setup and reporting framework; differences can alter peak picking and intensities.
3) Impurities/mixed phases: Evaluate whether the competitor material is a pure β-form or a mixture. Mixed-phase patterns can produce additional peaks that can either still fall under “essentially” or can defeat the claim depending on the tribunal’s view.
If evaluating process risk
1) Solvent system match: Check if the process uses water or isopropanol + water with dissolution to completion.
2) Cooling logic: Validate that the crystallization is achieved through progressive cooling after dissolution.
3) Seeding step: If crystallization is performed without seeding, that may avoid claim 3 while still implicating claim 2.
If evaluating product formulation risk
- Confirm whether the marketed solid product uses the β-crystalline form as active ingredient; carriers are unlikely to be a meaningful escape route given claim 4’s broad excipient language.
Key Takeaways
- US 7,361,649 is a polymorph patent: the core protection is Claim 1’s β-crystalline form of ivabradine hydrochloride defined by a specific PXRD signature (34 peak entries with 2θ, counts, ray area, FWHM, and d-spacing).
- Claim scope spans the product and its lifecycle: Claim 2 covers preparation by dissolution in water or isopropanol-water followed by progressive cooling, Claim 3 adds seeding, Claim 4 covers solid compositions using the β-form as active, and Claim 5 covers methods of treating angina, myocardial infarct, and heart failure.
- Design-arounds are likely pathway-based: avoiding the β-form PXRD signature (alternative polymorph) or changing manufacturing conditions outside the enumerated solvent systems and cooling/dissolution structure are the most direct off-ramps.
- FTO turns on analytical proof: PXRD classification and measurement method comparability will drive both infringement and validity outcomes.
FAQs
1) Is the β-form defined by 2θ peak positions only?
No. Claim 1 defines the β-form by a full PXRD dataset that includes peak height (counts), ray area (counts × degrees), FWHM (degrees), and interplanar distance d (Å), not just 2θ.
2) Do the process claims require isopropanol?
Claim 2 includes two options: water-only, or ivabradine HCl with isopropanol plus water. Isopropanol is required only for the second option.
3) Does seeding need to occur to infringe Claim 2?
No. Seeding is only required in dependent Claim 3. Claim 2 can be implicated without seeding.
4) Can a solid dosage form escape Claim 4 by changing excipients?
Claim 4 only requires pharmaceutically acceptable inert non-toxic carriers. Carrier changes alone do not remove coverage if the active ingredient is still the claimed β-form.
5) Does Claim 5 protect all cardiovascular uses of ivabradine?
No. Claim 5 limits treatment to conditions selected from angina pectoris, myocardial infarct, and heart failure.
References
[1] United States Patent No. 7,361,649.
